UBI Stock Overview
Through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices used in healthcare (point-of-care), wine, food, and agriculture industries in Australia, the Americas, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Universal Biosensors, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.087 |
| 52 Week High | AU$0.30 |
| 52 Week Low | AU$0.083 |
| Beta | 1.05 |
| 1 Month Change | -17.14% |
| 3 Month Change | -30.40% |
| 1 Year Change | -50.29% |
| 3 Year Change | -89.88% |
| 5 Year Change | -50.29% |
| Change since IPO | -91.30% |
Recent News & Updates
Recent updates
We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully
Dec 11
We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully
Nov 09We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate
May 03We Think Universal Biosensors (ASX:UBI) Needs To Drive Business Growth Carefully
Jan 12We're Keeping An Eye On Universal Biosensors' (ASX:UBI) Cash Burn Rate
Oct 10Companies Like Universal Biosensors (ASX:UBI) Are In A Position To Invest In Growth
Apr 28We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth
May 13Should You Take Comfort From Insider Transactions At Universal Biosensors, Inc. (ASX:UBI)?
Feb 24We Think Universal Biosensors (ASX:UBI) Can Afford To Drive Business Growth
Jan 20The Universal Biosensors (ASX:UBI) Share Price Has Gained 95% And Shareholders Are Hoping For More
Dec 15Shareholder Returns
| UBI | AU Medical Equipment | AU Market | |
|---|---|---|---|
| 7D | 2.4% | 1.3% | 1.3% |
| 1Y | -50.3% | 10.1% | 10.3% |
Return vs Industry: UBI underperformed the Australian Medical Equipment industry which returned 10.1% over the past year.
Return vs Market: UBI underperformed the Australian Market which returned 10.3% over the past year.
Price Volatility
| UBI volatility | |
|---|---|
| UBI Average Weekly Movement | 9.7% |
| Medical Equipment Industry Average Movement | 10.1% |
| Market Average Movement | 7.9% |
| 10% most volatile stocks in AU Market | 16.4% |
| 10% least volatile stocks in AU Market | 2.9% |
Stable Share Price: UBI has not had significant price volatility in the past 3 months compared to the Australian market.
Volatility Over Time: UBI's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 80 | John Sharman | www.universalbiosensors.com |
Universal Biosensors, Inc., through its subsidiaries, designs and develops electrochemical cells (strips) used in conjunction with point-of-use devices used in healthcare (point-of-care), wine, food, and agriculture industries in Australia, the Americas, Europe, and internationally. The company manufactures and distributes Prothrombin Time International Normalized Ratio coagulation test strips and Xprecia Stride and Xprecia Prime medical devices to monitor the effect of the anticoagulant therapy warfarin; and Sentia wine testing products, such as free SO2, malic acid, glucose, fructose, total acid, and titratable acidity. It also offers non-diagnostic laboratory services and performs coagulation testing services.
Universal Biosensors, Inc. Fundamentals Summary
| UBI fundamental statistics | |
|---|---|
| Market cap | AU$26.53m |
| Earnings (TTM) | -AU$12.39m |
| Revenue (TTM) | AU$7.08m |
3.7x
P/S Ratio-2.1x
P/E RatioIs UBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| UBI income statement (TTM) | |
|---|---|
| Revenue | AU$7.08m |
| Cost of Revenue | AU$3.05m |
| Gross Profit | AU$4.03m |
| Other Expenses | AU$16.43m |
| Earnings | -AU$12.39m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.042 |
| Gross Margin | 56.95% |
| Net Profit Margin | -175.04% |
| Debt/Equity Ratio | 0% |
How did UBI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/31 13:55 |
| End of Day Share Price | 2025/01/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Universal Biosensors, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Tara Speranza | Bell Potter |
| Shane Storey | Wilsons Advisory and Stockbroking Ltd. |